Procter & Gamble will most likely not benefit from an improvement in China and its personal health care category in its upcoming results, set to be the second consecutive quarter in which the consumer goods giant’s organic sales growth could be a bit softer than expected, Barclays analysts say in a research note. Still, Procter & Gamble continues to show significant volume growth and market share gains across most of its focus markets, including the U.S. and Western Europe, the analysts add. Barclays lowers its 3Q organic sales growth estimate by 60 basis points to 3%, but raises its recommendation on the stock to $168 from $165 previously. Shares fall 0.4% to $155.22.